Multidisciplinary care of laryngeal cancer

Journal of Oncology Practice

Volumn 12, Issue 8, 2016, Pages 717-724

  Salvador Coloma, Carmen ^a   Cohen, Ezra ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; GLOTTIS; HUMAN; INDUCTION CHEMOTHERAPY; LARYNGECTOMY; LARYNX CANCER; MULTIMODALITY CANCER THERAPY; REVIEW; LARYNGEAL NEOPLASMS; PATHOLOGY;

COMBINED MODALITY THERAPY; HUMANS; LARYNGEAL NEOPLASMS; NEOPLASM STAGING;

EID: 84981710189     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2016.014225     Document Type: Review

References (54)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Globocan. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (2011)
3. Hoffman HT, Porter K, Karnell LH, et al: Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival. Laryngoscope 116:1-13, 2006
4. DeVita VT Jr, Hellman TS, Rosenberg SA: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (ed 10). Philadelphia: Wolters Kluwer Health, 2016
5. Edge S, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer-Verlad, 2010.
6. Jones AS, Fish B, Fenton JE, et al: The treatment of early laryngeal cancers (T1-T2 N0): Surgery or irradiation? Head Neck 26:127-135, 2004
7. Tamura Y, Tanaka S, Asato R, et al: Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years. Acta Otolaryngol Suppl, 62-65, 2007
8. Stoeckli SJ, Schnieper I, Huguenin P, et al: Early glottic carcinoma: Treatment according patient's preference? Head Neck 25:1051-1056, 2003
9. Mendenhall WM, Werning JW, Hinerman RW, et al: Management of T1-T2 glottic carcinomas. Cancer 100:1786-1792, 2004
10. Pfister DG, Laurie SA, Weinstein GS, et al: American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24:3693-3704, 2006
11. Aaltonen LM, Rautiainen N, Sellman J, et al: Voice quality after treatment of early vocal cord cancer: A randomized trial comparing laser surgery with radiation therapy. Int J Radiat Oncol Biol Phys 90:255-260, 2014
12. Sykes AJ, Slevin NJ, Gupta NK, et al: 331 cases of clinically node-negative supraglottic carcinoma of the larynx: A study of a modest size fixed field radiotherapy approach. Int J Radiat Oncol Biol Phys 46:1109-1115, 2000
13. Paisley S, Warde PR, O'Sullivan B, et al: Results of radiotherapy for primary subglottic squamous cell carcinoma. Int J Radiat Oncol Biol Phys 52:1245-1250, 2002
14. 2 laser cordectomy for early-stage glottic carcinoma: A long-term follow-up of 156 cases. Laryngoscope 112:370-374, 2002
15. Mendenhall WM, Amdur RJ, Morris CG, et al: T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19:4029-4036, 2001
16. Taylor SM, Kerr P, Fung K, et al: Treatment of T1b glottic SCC: Laser vs. radiation - a Canadian multicenter study. J Otolaryngol Head Neck Surg 42:22, 2013
17. Higgins KM, Shah MD, Ogaick MJ, et al: Treatment of early-stage glottic cancer: Meta-analysis comparison of laser excision versus radiotherapy. J Otolaryngol Head Neck Surg 38:603-612, 2009
18. Yamazaki H, Nishiyama K, Tanaka E, et al: Radiotherapy for early glottic carcinoma (T1N0M0): Results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64:77-82, 2006
19. Beadle BM, Liao KP, Elting LS, et al: Improved survival using intensity-modulated radiation therapy in head and neck cancers: a - Medicare analysis. Cancer 120:702-710, 2014
20. Zumsteg ZS, Riaz N, Jaffery S, et al: Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. Oral Oncol 51:716-723, 2015
21. Nonoshita T, Shioyama Y, Kunitake N, et al: Retrospective analysis: Concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma. Fukuoka Igaku Zasshi 100:26-31, 2009
22. Sachse F, Stoll W, Rudack C: Evaluation of treatment results with regard to initial anterior commissure involvement in early glottic carcinoma treated by external partial surgery or transoral laser microresection. Head Neck 31:531-537, 2009
23. Wuthrick EJ, Zhang Q, Machtay M, et al: Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33:156-164, 2015
24. Gourin CG, Conger BT, Sheils WC, et al: The effect of treatment on survival in patients with advanced laryngeal carcinoma. Laryngoscope 119:1312-1317, 2009
25. Vikram B, Strong EW, Shah JP, et al: Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg 6:720-723, 1984
26. Kramer S, Gelber RD, Snow JB, et al: Combined radiation therapy and surgery in the management of advanced head and neck cancer: Final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 10:19-30, 1987
27. Holsinger FC, Nussenbaum B, Nakayama M, et al: Current concepts and new horizons in conservation laryngeal surgery: An important part of multidisciplinary care. Head Neck 32:656-665, 2010
28. Akbas Y, Demireller A: Oncologic and functional results of supracricoid partial laryngectomy with cricohyoidopexy. Otolaryngol Head Neck Surg 132:783-787, 2005
29. Paleri V, Thomas L, Basavaiah N, et al: Oncologic outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma: A systematic review and meta-analysis of English-language literature. Cancer 117:2668-2676, 2011
30. Brockstein BE, Stenson KM, Sher DJ: Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx. UpToDate, 2016. http://www.uptodate.com/contents/treatment-of-locoregionally-advanced-stage-iii-and-iv-head-and-neck-cancer-the-larynx-and-hypopharynx
31. Grover S, Swisher-McClure S, Mitra N, et al: Total laryngectomy versus larynx preservation for t4a larynx cancer: Patterns of care and survival outcomes. Int J Radiat Oncol Biol Phys 92:594-601, 2015
32. Timme DW, Jonnalagadda S, Patel R, et al: Treatment selection for T3/T4a laryngeal cancer: Chemoradiation versus primary surgery. Ann Otol Rhinol Laryngol 124:845-851, 2015
33. Stenson KM, Maccracken E, Kunnavakkam R, et al: Chemoradiation for patients with large-volume laryngeal cancers. Head Neck 34:1162-1167, 2012
34. Pignon JP, le Maître A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
35. Cooper JS, Zhang Q, Pajak TF, et al: Long-term follow-up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84:1198-1205, 2012
36. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
37. Lefebvre JL, Andry G, Chevalier D, et al: Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 23:2708-2714, 2012
38. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
39. Lefebvre JL, Chevalier D, Luboinski B, et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. J Clin Oncol 22, 2004 (suppl, abstr 5531)
40. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
41. Forastiere AA, Zhang Q, Weber RS, et al: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845-852, 2013
42. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
43. Vokes EE: Competing roads to larynx preservation. J Clin Oncol 31:833-835, 2013
44. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994
45. Domenge C, Hill C, Lefebvre JL, et al: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 83:1594-1598, 2000
46. Pignon JP, Bourhis J, Domenge C: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355:949-955, 2000
47. Pignon JP, Syz N, Posner M, et al: Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 15:331-40, 2004
48. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996
49. Worden FP, Kumar B, Lee JS, et al: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. Clin Oncol 26:3138-3146, 2008
50. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
51. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
52. Janoray G, Pointreau Y, Garaud P, et al: Long-term results of GORTEC 2000-01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation. J Clin Oncol 33, 2015 (abstr 6002)
53. Paccagnella A, Ghi MG, Loreggian L, et al: Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study. Ann Oncol 21:1515-1522, 2010
54. Lefebvre JL, Pointreau Y, Rolland F, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol 31:853-859, 2013